Whole-body FDG-PET imaging in the management of patients with cancer

被引:167
作者
Hustinx, R
Bénard, F
Alavi, A
机构
[1] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA 19104 USA
[2] Ctr Hosp Univ, Div Nucl Med, Liege, Belgium
[3] Ctr Hosp Univ Sherbrooke, Div Nucl Med, Sherbrooke, PQ, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1053/snuc.2002.29272
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging is increasingly used for the management of patients with cancer. The technique is now well accepted by most physicians as an effective complement to the existing imaging modalities. For many malignancies, PET achieves high sensitivity and specificity. The critical role of this powerful technique is realized increasingly in the day-to-day practice of oncology. This is particularly true for the management of patients with non-small-cell lung cancer (NSCLC). The contribution of PET for the selection of patients eligible for curative treatments in this setting is well established. Convincing data also exist to support the use of PET for evaluating patients with recurrent colorectal carcinoma, for staging and restaging lymphomas, and for diagnosing recurrent thyroid carcinoma in the presence of elevated thyroglobulin and negative I-131 scans. Other indications include staging of various recurrent malignancies, such as breast cancer, melanoma, and head and neck and gynecologic carcinomas. Existing data are limited for the determination of the impact of PET in certain malignancies, and further studies, which should include outcome information, will allow clarification of the role of this modality for such indications. Despite the small number of studies specifically designed to assess changes in management plans for some malignancies after performing PET the overall favorable results are encouraging enough at this time to include this modality as an essential element of the practice of modern oncology. Finally, the evolving role of PET imaging as a predictor of response after local or systemic treatment may add a major dimension to the application of this novel technique. Copyright (C) 2002 by WB. Saunders Company.
引用
收藏
页码:35 / 46
页数:12
相关论文
共 144 条
  • [1] Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors
    Aassar, OS
    Fischbein, NJ
    Caputo, GR
    Kaplan, MJ
    Price, DC
    Singer, MI
    Dillon, WP
    Hawkins, RA
    [J]. RADIOLOGY, 1999, 210 (01) : 177 - 181
  • [2] Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma
    Acland, KM
    Healy, C
    Calonje, E
    O'Doherty, M
    Nunan, T
    Page, C
    Higgins, E
    Russell-Jones, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2674 - 2678
  • [3] Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
    Adams, S
    Baum, RP
    Stuckensen, T
    Bitter, K
    Hör, G
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) : 1255 - 1260
  • [4] EVALUATION OF BREAST MASSES AND AXILLARY LYMPH-NODES WITH [F-18] 2-DEOXY-2-FLUORO-D-GLUCOSE PET
    ADLER, LP
    CROWE, JP
    ALKAISI, NK
    SUNSHINE, JL
    [J]. RADIOLOGY, 1993, 187 (03) : 743 - 750
  • [5] Alnafisi NS, 2000, J NUCL MED, V41, P1010
  • [6] Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans
    Altenvoerde, G
    Lerch, H
    Kuwert, T
    Matheja, P
    Schafers, M
    Schober, O
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 1998, 383 (02) : 160 - 163
  • [7] Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses
    Anzai, Y
    Carroll, WR
    Quint, DJ
    Bradford, CR
    Minoshima, S
    Wolf, GT
    Wahl, RL
    [J]. RADIOLOGY, 1996, 200 (01) : 135 - 141
  • [8] Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose:: Use and limitations
    Avril, N
    Rosé, CA
    Schelling, M
    Dose, J
    Kuhn, W
    Bense, S
    Weber, W
    Ziegler, S
    Graeff, H
    Schwaiger, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) : 3495 - 3502
  • [9] Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose
    Avril, N
    Dose, J
    Janicke, F
    Ziegler, S
    Romer, W
    Weber, W
    Herz, M
    Nathrath, W
    Graeff, H
    Schwaiger, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) : 1204 - 1209
  • [10] Avril N, 2001, J NUCL MED, V42, P9